Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
438 In vivo Engineered CAR-T cells for oncology using a surface-engineered lentivirus platform: nonclinical safety and biodistribution
Compose a Response to This Article
Other responses
No responses have been published for this article.
